Thetis Pharmaceuticals Selected to Present TP-317 Program at IBD Innovate Conference

Novel Resolvin-based drug candidate offers potential first-in-class, oral, small molecule therapy for IBD

BRANFORD, CT – (November 13, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing novel Resolvin-based therapies to treat inflammatory diseases, was selected by the Crohn’s & Colitis Foundation to present on TP-317, its lead drug candidate for inflammatory bowel disease (IBD), at the IBD Innovation Summit held at the New York Academy of Medicine on November 13th, 2018.

Dr. Matthew Hanley, Director of R&D at Thetis and lead author of the presentation poster, commented: “We are excited to present the findings from our translational study using IBD patient tissue explants, which support the potential efficacy of TP-317 for treatment of IBD. As a novel salt of Resolvin E1, TP-317 offers a fundamentally new approach to IBD treatment based on promoting inflammation resolution and mucosal healing.”

Gary Mathias, Co-founder and Chief Executive Officer, commented: “There is a major unmet need for safe oral therapies for the 1.5 million patients in the U.S. suffering from IBD. TP-317 is positioned as a potential first-in-class, safe, oral agent for treatment of ulcerative colitis and Crohn’s Disease patients not well controlled on first-line therapy. This segment is a major part of the patient population that has few options other than escalating to biologics or other immunosuppressive therapies.”

About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company developing novel small molecule therapies for the treatment of gastrointestinal inflammatory diseases. Thetis’ HEALER technology platform enables the pharmaceutical development of Resolvins, a novel class of molecules with the potential to transform the treatment of chronic inflammatory diseases based on resolving inflammation and promoting tissue repair without compromising immune function. Its lead candidate, TP-317, is a potential first-in-class, safe, oral therapy for mild-to-moderate IBD patients. Thetis was recently awarded a $2.3 million Fast Track NIH grant to develop TP-317 for ulcerative colitis.

For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).

Contact Information
Aaron Mathias
Director of Business Development
amathias@thetispharma.com